The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice
- PMID: 15991997
- DOI: 10.1517/13543784.7.4.607
The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice
Abstract
The ability to produce a diverse repertoire of fully human monoclonal antibodies (mAbs) may have significant applications to human therapy. This update describes the creation of a novel tool for the production of therapeutic human mAbs: a mouse strain engineered to produce a large range of human antibodies in the absence of mouse antibodies. This strain, XenoMouse, has been generated by the introduction of large segments of human immunoglobulin loci, containing the majority of the human antibody gene repertoire, into mice deficient in mouse antibody production. The mice produce a diverse array of authentic fully human IgGkappa antibodies. Upon immunisation with multiple human antigens the mice generate large panels of high affinity, antigen-specific fully human mAbs with therapeutic activities. XenoMouse-derived hybridomas were shown to be stable, producing significant levels of human mAbs. XenoMouse technology represents an efficient and reliable tool for the production of therapeutic human mAbs, which can accelerate the evaluation and validation of antibody therapy in human disease.
Similar articles
-
Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies.J Immunol Methods. 1999 Dec 10;231(1-2):11-23. doi: 10.1016/s0022-1759(99)00137-4. J Immunol Methods. 1999. PMID: 10648924 Review.
-
Production and selection of antigen-specific fully human monoclonal antibodies from mice engineered with human Ig loci.Adv Drug Deliv Rev. 1998 Apr 6;31(1-2):33-42. doi: 10.1016/s0169-409x(97)00092-6. Adv Drug Deliv Rev. 1998. PMID: 10837616
-
Production of fully human antibodies by transgenic mice.Curr Opin Biotechnol. 1995 Oct;6(5):561-6. doi: 10.1016/0958-1669(95)80093-x. Curr Opin Biotechnol. 1995. PMID: 7579668 Review.
-
From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice.Nat Biotechnol. 2007 Oct;25(10):1134-43. doi: 10.1038/nbt1337. Nat Biotechnol. 2007. PMID: 17921999
-
Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci.J Immunol. 2002 Jul 1;169(1):595-605. doi: 10.4049/jimmunol.169.1.595. J Immunol. 2002. PMID: 12077293
Cited by
-
Strategies for Generating Diverse Antibody Repertoires Using Transgenic Animals Expressing Human Antibodies.Front Immunol. 2018 Mar 7;9:460. doi: 10.3389/fimmu.2018.00460. eCollection 2018. Front Immunol. 2018. PMID: 29563917 Free PMC article.
-
Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.Invest New Drugs. 2010 Oct;28(5):561-74. doi: 10.1007/s10637-009-9291-z. Epub 2009 Jul 21. Invest New Drugs. 2010. PMID: 19626278
LinkOut - more resources
Full Text Sources
Other Literature Sources
